Clinical Trial Update: Clinical Trial of HY004 Cell Injection in the Treatment of Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma [Phase 1, Phase 2]

View source ↗

Summary

The HY004 cell injection trial for relapsed or refractory B-cell non-Hodgkin lymphoma has been withdrawn.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-hodgkin Lymphoma

Drugs mentioned

• HY004 cell injection

Snippet

Sponsor: Juventas Cell Therapy Ltd. | Conditions: Non-hodgkin Lymphoma | Phase 1, Phase 2 | Status: WITHDRAWN